Press release: Pivot Park Screening Centre Presents Cutting-edge Research on the Quest for Antiplatelet Drugs
Oss, the Netherlands, 22 March 2024 – Pivot Park Screening Centre, a CRO that offers assay development, lab automation, uHTS and hit-to-lead services for early drug discovery projects, is thrilled to share the paper published in Nature in which Saman Honarnejad – Chief Scientific Officer at Pivot Park Screening Centre – participated.
The focus of the research lies in Ultra-high Throughput-based Screening for the Discovery of Antiplatelet Drugs Affecting Receptor Dependent Calcium Signaling Dynamics.
ABSTRACT
Distinct platelet activation patterns are elicited by the tyrosine kinase-linked collagen receptor glycoprotein VI (GPVI) and the G-protein coupled protease-activated receptors (PAR1/4) for thrombin. This is reflected in the different platelet Ca2+ responses induced by the GPVI agonist collagen-related peptide (CRP) and the PAR1/4 agonist thrombin. Using a 96 well-plate assay with human Calcium-6-loaded platelets and a panel of 22 pharmacological inhibitors, we assessed the cytosolic Ca2+ signaling domains of these receptors and developed an automated Ca2+ curve algorithm. The algorithm was used to evaluate an ultra-high throughput (UHT) based screening of 16,635 chemically diverse small molecules with orally active physicochemical properties for effects on platelets stimulated with CRP or thrombin. Stringent agonist-specific selection criteria resulted in the identification of 151 drug-like molecules, of which three hit compounds were further characterized. The dibenzyl formamide derivative ANO61 selectively modulated thrombin-induced Ca2+ responses, whereas the aromatic sulfonyl imidazole AF299 and the phenothiazine ethopropazine affected CRP-induced responses. Platelet functional assays confirmed selectivity of these hits. Ethopropazine retained its inhibitory potential in the presence of plasma, and suppressed collagen-dependent thrombus buildup at arterial shear rate. In conclusion, targeting of platelet Ca2+ signaling dynamics in a screening campaign has the potential of identifying novel platelet-inhibiting molecules.
Explore further details about the article here.
Find more news here.